Subcutaneous immunoglobulin replacement in primary immunodeficiencies
- PMID: 15207776
- DOI: 10.1016/j.clim.2004.02.002
Subcutaneous immunoglobulin replacement in primary immunodeficiencies
Abstract
The use of small portable pumps for subcutaneous infusion of IgG in patients with primary immunodeficiencies was introduced more than 20 years ago. In the US, i.v.i.g. became more popular, but in other countries, many patients use the subcutaneous route. Pharmacokinetics of IgG differ when smaller doses are given more frequently, as is commonly done with subcutaneous regimens, as compared to the large boluses given every 21-28 days in most i.v. regimens. Differences include lower peaks and higher troughs, which may be preferable for some patients. Advantages of the subcutaneous route include increased patient autonomy, decreased systemic adverse effects, and the lack of a requirement for vascular access. Disadvantages include limitation in the volume that can be administered at any one time, necessitating frequent dosing; and the requirement for reliability if a patient is to self or home infuse. Obstacles may be encountered because no preparation of IgG is currently licensed for subcutaneous use in the US. Subcutaneous IgG replacement may be preferable to i.v. infusions or i.m. injections for carefully selected patients.
Similar articles
-
Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies.Pediatrics. 1996 Dec;98(6 Pt 1):1127-31. Pediatrics. 1996. PMID: 8951264
-
Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes.Immunol Allergy Clin North Am. 2008 Nov;28(4):803-19, ix. doi: 10.1016/j.iac.2008.06.006. Immunol Allergy Clin North Am. 2008. PMID: 18940575 Review.
-
Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.Adv Ther. 2011 Jul;28(7):521-33. doi: 10.1007/s12325-011-0036-y. Epub 2011 Jun 14. Adv Ther. 2011. PMID: 21681653 Review.
-
[Treatment of patients with primary antibody deficiencies in Germany].Klin Padiatr. 2005 Sep-Oct;217(5):276-80. doi: 10.1055/s-2004-820297. Klin Padiatr. 2005. PMID: 16167275 German.
-
Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies.Clin Exp Immunol. 2011 Jun;164(3):357-64. doi: 10.1111/j.1365-2249.2011.04376.x. Epub 2011 Mar 17. Clin Exp Immunol. 2011. PMID: 21413943 Free PMC article.
Cited by
-
Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK.Am J Transplant. 2015 Apr;15(4):1014-20. doi: 10.1111/ajt.13083. Epub 2015 Mar 3. Am J Transplant. 2015. PMID: 25736704 Free PMC article.
-
Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.PLoS One. 2016 Aug 4;11(8):e0159993. doi: 10.1371/journal.pone.0159993. eCollection 2016. PLoS One. 2016. PMID: 27490101 Free PMC article.
-
Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.J Clin Immunol. 2006 Jan;26(1):65-72. doi: 10.1007/s10875-006-8905-x. J Clin Immunol. 2006. PMID: 16418804
-
Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy.Qual Life Res. 2005 Sep;14(7):1683-91. doi: 10.1007/s11136-005-1746-x. Qual Life Res. 2005. PMID: 16119180
-
Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.J Clin Immunol. 2019 Nov;39(8):814-822. doi: 10.1007/s10875-019-00705-5. Epub 2019 Nov 1. J Clin Immunol. 2019. PMID: 31673923 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
